<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance MechanismsJessica L.F. Teh, Andrew E. Aplin|Cancer Discovery|2018Cited by 77